Published in J Endocrinol on November 01, 2006
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer (2008) 2.10
Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol (2011) 1.54
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.40
Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta (2013) 1.27
Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy (2012) 1.16
Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol (2011) 1.10
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One (2012) 1.03
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol (2010) 0.99
Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid (2013) 0.94
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem (2012) 0.93
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91
Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne) (2012) 0.89
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther (2012) 0.86
Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med Mol Imaging (2011) 0.85
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol (2012) 0.83
Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One (2013) 0.82
Anaplastic thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.82
Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin. Nucleus (2011) 0.82
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res (2010) 0.82
Nuclear protein isoforms: implications for cancer diagnosis and therapy. J Cell Biochem (2011) 0.81
Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line. Int J Endocrinol (2015) 0.81
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J Surg Res (2014) 0.80
Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. Cancer Gene Ther (2015) 0.77
Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS One (2013) 0.77
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death. Am J Transl Res (2013) 0.77
DNA and histone deacetylases as targets for neuroblastoma treatment. Interdiscip Toxicol (2010) 0.77
Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). Int J Clin Exp Pathol (2015) 0.76
Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors. ACS Med Chem Lett (2015) 0.76
Impaired expression of DICER and some microRNAs in HBZ expressing cells from acute adult T-cell leukemia patients. Oncotarget (2016) 0.75
Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial. Int J Endocrinol (2016) 0.75
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem (2007) 1.61
Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc Res (2003) 1.51
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem (2009) 1.43
Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol (2005) 1.39
Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology (2007) 1.26
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer (2007) 1.24
Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol (2006) 1.24
AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging (2010) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med (2006) 1.16
4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol (2004) 1.14
Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med (2007) 1.13
Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab (2004) 1.08
Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes (2008) 1.04
Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol (2010) 1.01
Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol (2007) 1.01
Oxidative stress impairs skeletal muscle repair in diabetic rats. Diabetes (2004) 1.01
Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology (2006) 0.99
Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab (2004) 0.99
Oxidative stress and kidney dysfunction due to ischemia/reperfusion in rat: attenuation by dehydroepiandrosterone. Kidney Int (2003) 0.99
Dehydroepiandrosterone modulates nuclear factor-kappaB activation in hippocampus of diabetic rats. Endocrinology (2002) 0.98
Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol (2006) 0.98
Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost (2003) 0.97
Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock (2008) 0.96
SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med (2009) 0.95
Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis. Am J Pathol (2004) 0.95
The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol Cell Endocrinol (2002) 0.95
Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer (2011) 0.95
Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab (2012) 0.93
Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic Biol Med (2010) 0.92
Ischemic preconditioning attenuates the oxidant-dependent mechanisms of reperfusion cell damage and death in rat liver. Liver Transpl (2002) 0.92
Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol (2012) 0.91
High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: a protective role for PPAR- δ agonism. Mediators Inflamm (2013) 0.91
Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment. Endocrinology (2005) 0.90
Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep (2007) 0.90
Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne) (2012) 0.89
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr (2011) 0.89
Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates. Am J Pathol (2003) 0.87
Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation. Life Sci (2003) 0.87
Oxytocin modulates estrogen receptor alpha expression and function in MCF7 human breast cancer cells. Int J Oncol (2002) 0.87
Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis (2009) 0.86
Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. Thyroid (2013) 0.86
Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina. J Am Coll Cardiol (2006) 0.86
Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med (2010) 0.86
Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol (2012) 0.85
Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett (2007) 0.85
Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension? J Hepatol (2005) 0.85
Ischaemic preconditioning modulates the activity of Kupffer cells during in vivo reperfusion injury of rat liver. Cell Biochem Funct (2003) 0.83
Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J Cancer Res Clin Oncol (2011) 0.83
Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. J Clin Endocrinol Metab (2008) 0.83
Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum. Basic Res Cardiol (2010) 0.82
High energy shock waves (HESW) enhance paclitaxel cytotoxicity in MCF-7 cells. Breast Cancer Res Treat (2003) 0.82
Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol (2013) 0.82
Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type 2 diabetic patients. Diabetes Care (2007) 0.80
High energy shock waves (HESW) for sonodynamic therapy: effects on HT-29 human colon cancer cells. Anticancer Res (2006) 0.79